CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma

Joseph D. Malaer, Porunelloor Mathew

Research output: Contribution to journalReview articleResearchpeer-review

10 Citations (Scopus)

Abstract

CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.

Original languageEnglish
Pages (from-to)1637-1641
Number of pages5
JournalAmerican Journal of Cancer Research
Volume7
Issue number8
StatePublished - 1 Jan 2017

Fingerprint

Multiple Myeloma
Natural Killer Cells
Immunotherapy
Natural Killer Cell Receptors
Antibody-Dependent Cell Cytotoxicity
T-Lymphocytes
Antibodies, Monoclonal, Humanized
Dendritic Cells
Monocytes
Anti-Idiotypic Antibodies
B-Lymphocytes
elotuzumab
Clinical Studies

Keywords

  • Antibody-based immunotherapy
  • CRACC
  • CS1
  • Elotuzumab
  • Multiple myeloma
  • SLAMF7

Cite this

@article{818eeea0986b48bbb488b765ae480701,
title = "CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma",
abstract = "CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.",
keywords = "Antibody-based immunotherapy, CRACC, CS1, Elotuzumab, Multiple myeloma, SLAMF7",
author = "Malaer, {Joseph D.} and Porunelloor Mathew",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "7",
pages = "1637--1641",
journal = "American Journal of Cancer Research",
issn = "2156-6976",
publisher = "e-Century Publishing Corporation",
number = "8",

}

CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma. / Malaer, Joseph D.; Mathew, Porunelloor.

In: American Journal of Cancer Research, Vol. 7, No. 8, 01.01.2017, p. 1637-1641.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma

AU - Malaer, Joseph D.

AU - Mathew, Porunelloor

PY - 2017/1/1

Y1 - 2017/1/1

N2 - CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.

AB - CS1 (also known as CD319, CRACC and SLAMF7) was identified as an NK cell receptor regulating immune functions. It is also expressed on B cells, T cells, Dendritic cells, NK-T cells, and monocytes. CS1 is overexpressed in multiple myeloma and makes it a target for immunotherapy. A humanized anti-CS1 antibody, Elotuzumab or Empliciti has shown promising results in clinical studies. This review focuses on the biology of CS1 in NK and other hematopoietic cells and multiple myeloma. Anti-CS1 mAb can activate natural cytotoxicity of NK cells as well as enhance ADCC (antibody-dependent cell-mediated cytotoxicity) and thus makes an effective target for immunotherapy of MM.

KW - Antibody-based immunotherapy

KW - CRACC

KW - CS1

KW - Elotuzumab

KW - Multiple myeloma

KW - SLAMF7

UR - http://www.scopus.com/inward/record.url?scp=85028059141&partnerID=8YFLogxK

M3 - Review article

VL - 7

SP - 1637

EP - 1641

JO - American Journal of Cancer Research

JF - American Journal of Cancer Research

SN - 2156-6976

IS - 8

ER -